2007
DOI: 10.1111/j.1479-828x.2007.00741.x
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: We found that factor V Leiden is a significant risk factor for placental abruption.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
9
1

Year Published

2009
2009
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(11 citation statements)
references
References 20 publications
1
9
1
Order By: Relevance
“…Some authors suggest that the factor V Leiden carriers have less blood during delivery compared with non-carriers. Our study confi rmed this suggestion (26,(33)(34)(35)(36).…”
Section: Discussionsupporting
confidence: 87%
“…Some authors suggest that the factor V Leiden carriers have less blood during delivery compared with non-carriers. Our study confi rmed this suggestion (26,(33)(34)(35)(36).…”
Section: Discussionsupporting
confidence: 87%
“…However, the data for homozygotes were obtained from a single small study and very wide confidence intervals (0.41-171.2) that incorporated 1 indicating lack of statistical significance. While these results were supported by two subsequent small (n = 55 and 180, respectively) case-control studies [46,47] that reported ORs of 9.12 (95% CI: 2.18-31.7) and 3.0 (95% CI: 1.4-6.7), respectively, for factor V Leiden heterozygotes, a larger nested study (n = 339) failed to find a link between adverse pregnancy outcomes and coagulation disorders, including the factor V Leiden mutation [21].…”
Section: Placental Abruptioncontrasting
confidence: 52%
“…Interestingly, one of the small casecontrol studies that had shown an association with the factor V Leiden mutation did not show an increased risk of placental abruption with this thrombophilia [47].…”
Section: Placental Abruptionmentioning
confidence: 95%
“…This theme remains controversial. There is no clear evidence of a direct relationship between carriage of inherited TM and higher risk of developing late pregnancy complications 8 , but in clinical practice the fact of carriage of any of the thrombophylic mutations in combination with pregnancy is rationale for prophylactic LMWH use during pregnancy. This preventive use of LMWH replaces the individual approach in observation of these carriers during pregnancy in terms of hemocoagulation changes, clinical status or emergence of additional transient risk factors.…”
Section: Discussionmentioning
confidence: 99%